Exact Sciences Revenue 2006-2021 | EXAS

Exact Sciences annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Exact Sciences revenue for the quarter ending June 30, 2021 was $0.435B, a 61.72% increase year-over-year.
  • Exact Sciences revenue for the twelve months ending June 30, 2021 was $1.712B, a 51.33% increase year-over-year.
  • Exact Sciences annual revenue for 2020 was $1.491B, a 70.19% increase from 2019.
  • Exact Sciences annual revenue for 2019 was $0.876B, a 92.82% increase from 2018.
  • Exact Sciences annual revenue for 2018 was $0.454B, a 70.86% increase from 2017.
Exact Sciences Annual Revenue
(Millions of US $)
2020 $1,491
2019 $876
2018 $454
2017 $266
2016 $99
2015 $39
2014 $2
2013 $4
2012 $4
2011 $4
2010 $5
2009 $5
2008 $-1
2007 $2
2006 $5
2005 $4
Exact Sciences Quarterly Revenue
(Millions of US $)
2021-06-30 $435
2021-03-31 $402
2020-12-31 $466
2020-09-30 $408
2020-06-30 $269
2020-03-31 $348
2019-12-31 $296
2019-09-30 $219
2019-06-30 $200
2019-03-31 $162
2018-12-31 $143
2018-09-30 $118
2018-06-30 $103
2018-03-31 $90
2017-12-31 $87
2017-09-30 $73
2017-06-30 $58
2017-03-31 $48
2016-12-31 $35
2016-09-30 $28
2016-06-30 $21
2016-03-31 $15
2015-12-31 $14
2015-09-30 $13
2015-06-30 $8
2015-03-31 $4
2014-12-31 $2
2014-09-30
2014-06-30
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
2008-12-31 $-0
2008-09-30 $-1
2008-06-30 $-0
2008-03-31 $0
2007-12-31 $-1
2007-09-30 $0
2007-06-30 $1
2007-03-31 $1
2006-12-31 $1
2006-09-30 $1
2006-06-30 $1
2006-03-31 $1
2005-12-31 $1
2005-09-30 $1
2005-06-30 $1
2005-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $17.016B $1.491B
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00